2012 - 2013 SABINSA CORPORATION 1

I N N O V AT I V E
I N G R E D I E N T S
I N S U P P O R T O F
W E I G H T
MA N A G E ME N T
AUTHORS:
MUHAMMED MAJ EED, PH. D. REZA KAMAREI , PH. D.
20 Lake Dr i ve , Ea s t Wi nds or, NJ 0 8 5 2 0
Te l : 7 3 2 . 777. 1111 Emai l : i nf o@s a bi ns a . c om We b: www. s a bi ns a . c om

Clven Lhls background, several lnnovauve naLural lngredlenLs LhaL

supporL welghL managemenL have been dlscovered and developed by
Sablnsa Corporauon, a verucally-lnLegraLed company. 8ased on Lhelr
mechanlsms of acuon, Lhese lngredlenLs may be dlvlded lnLo four groups.
2012 - 2013 SABINSA CORPORATION 2
!"#$% '( )*+"*,- .,/ !.")*+"*,-
!"#$% )( 01.,!."/-
23#45*,.6#, #7 !.")*+"*,- .,/ 8#"901.,-: %;$9 <*#=1"*,1->
!"#$% <( 8#"901.,-
!"#$% ?( 8.51,#;-
<@A')B@CD @E!FD?@DEBG
!"#$% '( )*+"*,- .,/ !.")*+"*,-
ClLrln and CarClLrln are exLracLed from Lhe frulL of Lhe planL Cotclolo comboqlo, whlch has a long hlsLory of
use ln lndlan foods (mosLly as an acldulanL). 1he bloacuve lngredlenLs of Lhls frulL are PydroxyclLrlc acld and
Carclnol (llg. 1 a & b).
2012 - 2013 SABINSA CORPORATION 3
GarCitrin

8*H I.( JK/"#LK3*+"*3 .3*/ 8*H I5( !."3*,#;

I> )*+"*,-
ClLrln conLalns only one of Lhe bloacuve lngredlenLs of Lhe Cotclolo
comboqlo frulL, namely, PydroxyclLrlc acld (PCA). PCA ls a derlvauve
of clLrlc acld, Lhe agenL LhaL glves clLrus frulLs (oranges, lemons) Lhelr
characLerlsuc LarL avor. ClLrln ls sLandardlzed for a mlnlmum of
30 PCA (ConLe, 1993, kaus eL al, 1993, 1hom, 1996).
8admaev and Ma[eed (1993) have conducLed a cllnlcal sLudy on ClLrln. 1he deslgn of Lhe cllnlcal sLudy was as
follows:

uurauon: 8 weeks, open eld, physlclan-conLrolled

Sub[ecLs: 42 women and 13 men

Age of Sub[ecLs: 20-64 years

ually uose:
o
300 mg ClLrln (l.e., 230 mg PCA), 3 umes a day (30-60 mln. before meals)
llg. 2 shows Lhe eecL of dally admlnlsLrauon of ClLrln on body welghL ln Lhls sLudy. As lL can be seen, Lhere
ls a modesL decrease ln body welghL aer 8 weeks - equally ln females and males. 1he mosL obvlous quesuon
ls abouL Lhe mechanlsm of acuon behlnd Lhe welghL loss. 1here are Lwo mechanlsms lnvolved here: lnhlbluon
of fauy acld synLhesls and sumulauon of fauy acld oxldauon ( oxldauon).
As far as lnhlbluon of fauy acld synLhesls ls concerned, PydroxyclLrlc Acld has 100 umes greaLer amnlLy for Lhe
enzyme clLraLe lyase, and, Lherefore, lL acLs as a poLenL lnhlblLor of clLraLe lyase. uue Lo Lhe lnhlbluon of
clLraLe lyase, very llule AceLyl CoA and Malonyl CoA are formed, whlch resulLs ln lnhlbluon of fauy acld
2012 - 2013 SABINSA CORPORATION 4
Female
B
o
d
y

W
e
i
g
h
t

(
l
b
s
)
Male All
250
200
150
100
50
0
Effect of daily administration of Citrin on body weight
Before Citrin
After 4 wks
After 8 wks)
llg. 2
synLhesls. As far as promouon of faL loss vla sumulauon of fauy acld oxldauon (or oxldauon) ls concerned,
fauy aclds are LransporLed lnLo mlLochondrla by llnklng wlLh L-carnlune. 1hls llnkage ls faclllLaLed by L-
carnlune Lransferase. As sLaLed above, ln Lhe presence of PCA, Malonyl CoA ls noL produced. 1he absence of
Malonyl CoA faclllLaLes Lhe oxldauon of fauy aclds.
ClLrln also aecLs appeuLe. llg 3 shows Lhe eecL of dally admlnlsLrauon of ClLrln on relauve appeuLe (self
assessmenL) ln Lhls sLudy. 1he way Lhls eecL happens ls as follows: 1he acuvauon of faL oxldauon by PCA ln
Lhe llver also Lends Lo sumulaLe gluconeogensls. 1hls replenlshes Lhe sLored glycogen sLorage ln llver. 1he hlgh
level of glycogen, as a resulL of hlgh glucose supply, ls LranslaLed by Lhe CenLral nervous SysLem as stote of
souety.
1he waLer-soluble poLasslum salL of ClLrln, l.e. ClLrln k, ls a self-amrmed C8AS (Cenerally 8ecognlzed As
Safe) subsLance wlLh Lhe recommended use level of up Lo 2,300 ppm ln selecLed non-alcohollc beverages (4.2
g/day for 70 kg person).
8ecenLly, a meLa-analysls of randomlzed cllnlcal Lrlals on Lhe use of Cotclolo exLracL (PydroxyclLrlc Acld) as a
welghL loss supplemenL was publlshed ln Lhe !ournal of CbeslLy (Cnakpoya eL al, 2011). 1he auLhors of Lhls
paper concluded LhaL Cotclolo exttocts/ncA coo coose sbott-tetm welqbt loss. 1be moqoltoJe of tbe e[ect ls
smoll." 1hls concluslon ls compauble wlLh Lhe small or modesL welghL loss shown ln llg 2. 1he reason for Lhls
observauon could posslbly be LhaL PCA ls poorly absorbed lnLo Lhe cyLosol of Lhe LargeL cell, llmlung lLs ablllLy
Lo lnhlblL clLraLe lyase. Whlle searchlng for an eecuve molecule LhaL faclllLaLes Lhe absorpuon of PCA lnLo Lhe
cyLosol, Lhe lngredlenL Cotclool became Lhe Lop candldaLe for conslderauon.
2012 - 2013 SABINSA CORPORATION 5
Female Male All
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Effect of daily administration of on relative appetite -
self assessment
Citrin
Before Citrin
After 4 wks
After 8 wks)
B
o
d
y

W
e
i
g
h
t

(
l
b
s
)
llg. 3
M> !.")*+"*,-
CarClLrln ls a paLenLed (uS7,063,861, Au773081, nZ318116, Lu1234209 & !4203943) producL comblnlng
Lhe welghL managemenL beneLs of hydroxyclLrlc acld wlLh Lhe bloavallablllLy-enhanclng eecLs of garclnol, a
polylsoprenylaLed benzophenone lsolaLed from Carclnla cambogla 1he recommended use level of CarClLrln
ls 300 mg whlch conLalns 230 mg PCA and 23 mg Carclnol - Lhree umes a day.
8admaev, Ma[eed and ConLe compared ClLrln and CarClLrln (lnlually called new ClLrln") ln a cllnlcal Lrlal.
ueslgn of Lhe cllnlcal sLudy was as follows:

auenLs: 46 overwelghL healLhy women

uose: 300 mg ClLrln or CarClurn, Lhree umes a day

uurauon: 12 weeks, double-bllnd

Condluons: no change ln dleL and exerclse

SafeLy parameLers: physlcal exam, pulse raLe, blood pressure

llg. 4 shows percenLage of welghL loss ln groups C (ClLrln) and nC (new ClLrln, l.e., CarClLrln) ln Lhls sLudy.
1hls cllnlcal Lrlal showed CarClLrln ls sLausucally and cllnlcally more eecuve Lhan ClLrln. nelLher ClLrln nor
CarClLrln produce any sub[ecuve or ob[ecuve slde eecLs. As far as Lhe role Carclnol plays Lo make CarClLrln
more eecuve Lhan ClLrln, lL ls posLulaLed LhaL Carclnol modulaLes regulaLory cell slgnal paLhways and,
Lherefore, faclllLaLes Lhe upLake of PCA lnLo Lhe cells
2012 - 2013 SABINSA CORPORATION 6
!"#$% <( 8#"901.,-
lorsLean ls an exLracL obLalned from Lhe drled rooLs of Lhe planL coleos fotskoblll. lnLeresungly, coleos
fotskoblll toots also have a hlsLory of food use ln lndla (as plckle or condlmenL). coleos fotskoblll has been
sLudled exLenslvely. 1he mosL recenL revlew ls a book chapLer uLled coleos fotskoblll LxLracL ln Lhe
ManagemenL of CbeslLy" wrluen by ur. Ma[eed, Lhe lounder and Chalrman of Sablnsa Corporauon.
1he bloacuve lngredlenL of lorsLean ls lorskolln, a Labdane dl-Lerpenold (llg. 3). lorsLean ls sLandardlzed
for mlnlmum 10 of Lhe bloacuve lngredlenL lorskolln (20 and 40 sLrengLhs are also avallable). SuggesLed
use level of lorsLean 10 ls 230 mg (whlch corresponds Lo 23 mg lorskolln), Lwlce a day, 30 mlnuLes before
meals.
As far as cllnlcal Lrlals are concerned, seven (7) cllnlcal sLudles have lnvesugaLed
Lhe emcacy of lorsLean for welghL loss. AlLhough emcacy was Lhe prlmary
purpose of Lhese Lrlals, parameLers relaLed Lo safeLy were also monlLored.
8esulLs of one of Lhe earllesL cllnlcal Lrlals on lorsLean (8admaev, Ma[eed, et ol,
2002) ls shown ln llg 6. ln Lhls 8-week, plloL open eld sLudy, 6 overwelghL women
recelved 300 mg lorsLean (or 30 mg lorskolln) per day. As lL can be seen, aer 8
weeks, Lhere was a conslderable welghL loss & faL loss, and lncrease ln lean body
mass.

2012 - 2013 SABINSA CORPORATION 7
8*H N(
10
8
6
4
2
0
-2
-4
-6
-8
-10
-
-
-
-
-
-
-
-
-
-
-
Mean Weight Loss (lbs)
Mean Body Fat (%)
Mean Lean Body Mass (%)
8*H O( D*HP+ Q11R G+$/K
llg. 7 shows anoLher cllnlcal Lrlal on lorsLean (8hagwaL et ol, 2004). ln Lhls 12-week, double-bllnd and
randomlzed sLudy, 60 obese sub[ecLs recelved 300 mg lorsLean (30 mg lorskolln) per day. As lL can be seen,
aer 12 weeks, Lhere was 1.73 kg of welghL loss ln Lhe LesL group, compared Lo 0.23 kg of welghL galn ln Lhe
placebo group.
2012 - 2013 SABINSA CORPORATION 8
llg. 8 shows yeL anoLher cllnlcal Lrlal on
lorsLean (kamaLh, 2004). ln Lhls 12-
week, randomlzed sLudy, 30 male and
female sub[ecLs recelved 230 mg of
lorsLean or lacebo capsules - Lwlce a
day. As shown, aer 12 weeks, Lhere ls
2.7 welghL loss and 1.8 faL loss ln
Lhe LesL group, compared Lo 0.9 and
0.2 for Lhe placebo group. Also, Lhere
ls 1.8 lncrease ln lean body mass ln
Lhe LesL group compared Lo 0.2
decrease ln Lhe lean body mass ln Lhe
placebo group.
8*H S( 8#"901., DT13+ #, Q1*HP+: <#/K )#,+1,+ .,/ 01., <#/K U.99 .V1" IM W11R9 2X.4.+P !" $%: MYYZ>
Conslderlng Lhe resulLs of Lhe cllnlcal sLudles presenLed above, one may ask whaL ls Lhe mechanlsm of acuon
of lorsLean?". llg. 9 graphlcally shows lorsLean's mechanlsms of acuon.
lorskolln, Lhe bloacuve lngredlenL ln lorsLean, faclllLaLes a cascade of
blochemlcal evenLs ln Lhe body. Speclcally, lorskolln acuvaLes Lhe
enzyme adenylaLe cyclase, Lhe maln enzyme lnvolved ln Lhe producuon
of cycllc adenoslne monophosphaLe, or cAM, referred Lo ln Lhe
llLeraLure as Lhe "second messenger.
lollowlng Lhe blochemlcal paLhway shown on Lhe rlghL of llg 9, cycllc
AM faclllLaLes Lhe acuon of "prlmary messengers" or varlous hormonal
and bloacuve subsLances ln Lhe body (such as lnsulln and LhyroLropln).
2012 - 2013 SABINSA CORPORATION 9
8*H [( U13P.,*94 #7 .36#, #7 8#"901.,-
8y faclllLaung hormonal acuon, cycllc AM may conLrlbuLe Lo Lhe lncrease
ln Lhe meLabollc raLe and Lhermogenesls. 1hese evenLs correspond Lo Lhe
bulldup of lean body mass.
lollowlng blochemlcal paLh shown on Lhe le of llg 9, an lncrease ln
cycllc AM leads Lo Lhe subsequenL acuvauon of proLeln klnase. roLeln
klnase has been shown Lo acuvaLe Lhe hormone sensluve llpase whlch ls
lnvolved ln Lhe breakdown of Lrlglycerldes - known as bulldlng blocks of
fauy ussue. 1hese evenLs correspond Lo Lhe decrease ln body faL.
As far as documenLed SafeLy ls concerned, lorsLean ls well-LoleraLed,
wlLhouL adverse slde eecLs. lorsLean aL 300mg/day (30 mg forskolln/
day) for up Lo 12 weeks, produced no slgnlcanL deLrlmenLal eecLs on
blochemlsLry, hemaLologlcal parameLers, blood pressure or Lhyrold
funcuons (CanLox, 2006).
2012 - 2013 SABINSA CORPORATION 10
!"#$% )( 01.,!."/-
LeanCard ls a proprleLary blend of CarClLrln, lorsLean and 8loerlne wlLh Lhe suggesLed use level of
300mg Lwo umes per day. 1he composluon of LeanCard bloacuve lngredlenLs ls as follows:
! CarClLrln (23 Lo 30 PCA + 2 Lo 3 Carclnol)
! lorsLean (4 Lo 3 lorskolln)
! 8loerlne (0.3 Lo 0.3 lperlne)
1he key polnL abouL LeanCard ls LhaL we are comblnlng Lwo dlerenL groups of bloacuve lngredlenLs wlLh
complemenLary mechanlsms of acuon for welghL managemenL. 1he Lhlrd lngredlenL, 8loerlne ls a cllnlcally
proven, naLural bloavallablllLy-enhancer for nuLrlenLs. lL may also have a role ln prevenung dlerenuauon of
adlpocyLes. 8loerlne ls a sLandardlzed exLracL obLalned from black pepper, conLalnlng 93-99 plperlne and
ls a self-amrmed C8AS subsLance wlLh Lhe recommended use level of 3mg/dose.
Ma[eed et ol (2009) conducLed a cllnlcal Lrlal Lo lnvesugaLe Lhe emcacy and safeLy of LeanCard. 1he
parameLers of Lhe sLudy were as follows:

ueslgn: placebo-conLrolled, randomlzed, double bllnd parallel-group

Sub[ecLs: 30 over-welghL sub[ecLs ln each group comprlslng of 24 Men and 26 Women ranglng ln age
from 23 Lo 33 years.

SLudy uurauon: 12 weeks

uosage: 300mg of Lhe LeanCard or lacebo, Lwlce a day

8*H\ IY shows LhaL
LeanCard caused
7.3 reducuon ln
Lhe boJy welqbt of
L h e L e s L g r o u p
compared Lo 1.1 ln
Lhe placebo group.
2012 - 2013 SABINSA CORPORATION 11
8*H\ II shows LhaL LeanCard caused 8.13 reducuon ln Lhe boJy fot of Lhe LesL group compared Lo 1.18 ln
Lhe placebo group.
8*H\ IM shows LhaL LeanCard caused 4.36 lncrease ln Lhe leoo boJy moss of Lhe LesL group compared Lo
0.67 ln Lhe placebo group. lurLhermore, LeanCard dld noL cause any slgnlcanL changes ln blood pressure
or hearL raLe, hemaLologlcal parameLers, llver funcuon, renal funcuon, Lhyrold funcuon, and plasma llpld
levels. 8ased on Lhe resulLs of Lhe above cllnlcal sLudy, lL ls concluded LhaL LeanCard ls an eecuve and
cllnlcally safe dleLary supplemenL ln supporL of welghL managemenL.
2012 - 2013 SABINSA CORPORATION 12
!"#$% ?( 8.51,#;-
labenol

ls an alpha-amylase lnhlblLory naLural exLracL obLalned from lboseolos volqotls (common bean,
kldney bean) LhaL blocks Lhe dlgesuon of dleLary sLarch. Alpha amylase caLalyzes Lhe hydrolysls of o-(1,4)
glycosldlc llnkages of sLarch. 1he alpha amylase lnhlblLor ls ldenued ln Lhe proLeln fracuon of Lhe bean.
labenol ls noL dlrecLly lnvolved ln Lhe welghL loss process. Powever, lL lndlrecLly supporLs welghL loss as lL
supporLs Lhe lnhlbluon of sugar formauon from sLarch break down. Amylase lnhlblLors also alLer Lhe amounL
and pauern of food lnLake and reduce welghL galn Lhrough lnduclng saueLy and lncreaslng carbohydraLe
dellvery Lo Lhe lleum and colon.
Lxcess sLarch ln Lhe dleL ls converLed Lo glucose ln Lhe Cl LracL and upon absorpuon ls converLed Lo faLs and
sLored ln Lhe body. An alpha-amylase lnhlblLor lnhlblLs Lhe dlgesuon of sLarch Lhereby poLenually lmprovlng
posLprandlal carbohydraLe Lolerance ln people wlLh low glucose Lolerance. As excess dleLary carbohydraLe ls
meLabollzed Lo faL, lnhlbluon of carbohydraLe dlgesuon helps ln welghL managemenL.
An amylase lnhlblLor obsLrucLs Lhe dlgesuon of sLarch and absorpuon of glucose. 1herefore amylase lnhlblLors
are valued ln condluons such as dlabeLes (Lo reduce blood sugar levels) and ln welghL managemenL. Slnce Lhe
alpha-amylase lnhlblLor proLeln blnds wlLh Lhe acuve slLes of alpha- amylase and prevenLs lLs sLarch
degradauon acuvlLy, lL ls also called SLarch 8locker".
l*H\ I] shows seeds of lboseolos volqotls and labenol's alpha amylase lnhlblLory acuon. labenol ls oered
ln Lwo sLrengLhs: SLandard labenol (each gram prevenLs dlgesuon of 120 grams sLarch) and labenol Max
(each gram prevenLs dlgesuon of 300 grams sLarch). 1he recommended dose of labenol ls 2.3 Lo 3.73 g
before meals and for labenol Max ls 1 Lo 1.3 g before meals.
2012 - 2013 SABINSA CORPORATION 13
1.2
1
0.8
0.6
0.4
0.2
0
0.825 0.55 0.275 0.1375 0.06825 SE
A
l
p
h
a
-
a
m
y
l
a
s
e
A
c
t
i
v
i
t
y

(
U
n
i
t
s
/
m
l
)
Inhibitor Concentration (mg/ml)
*SE - Standard: amylase enzyme (Sigma)
Alpha-Amylase Inhibitory action of Fabenol
F171"1,319
- 8admaev v, Ma[eed M (1993) Cpen eld, physlclan conLrolled, cllnlcal evaluauon of boLanlcal welghL loss
formula ClLrln: nuLracon 93: nuLraceuucals, uleLary SupplemenLs and luncuonal loods. uay Cne
(sponsored by global buslness research) publlshed ln Lhe symposlum book.
- 8admaev v, Ma[eed M, and ConLe A (1999) Carclnla cambogla for welghL loss. !AMA: vol 282, no.3.
- 8agwaL AM, !oshl 8, !oshl AS et ol (2004) A 8andomlzed uouble-8llnd Cllnlcal 1rlal Lo lnvesugaLe Lhe emcacy
and safeLy of lorsLean ln lncreaslng lean body mass. Mumbal, lndla: Shrl. C.8. aLel 8esearch CenLer for
ChemlsLry and 8lologlcal Sclences [for Sablnsa Corporauon].
- CanLox PealLh Sclences lnLernauonal (2006) LxperL 8evlew 8eporL on SafeLy of lorsLean, CnLarlo, Canada.
- ConLe AA (1993) A non-rescrlpuon AlLernauve ln welghL reducuon 1herapy. 1he 8arlaLrlclan: 17-19.
- kamaLh MS (2004) 8esearch 8eporL, Lmcacy and SafeLy of lorsLean ln lncreaslng lean body mass ln Class l
Cbese Sub[ecLs, kasLurba Medlcal College, Manlpal, lndla.
- kaus C8, ullln u, arker Lk, kelLh L, kelLh S (1993) 8educuon of body faL as a funcuon of Laklng a dleLary
supplemenL conLalnlng garclnla cambogla exLracL, chromlum plcollnaLe and L-carnlune - a double-bllnd
placebo conLrolled sLudy. AbsLracL/posLer presenLed aL Lhe symposlum on obeslLy organlzed by Lhe Mexlcan
Socledad Medlcal del SuresLe para el LsLudlo de la Cbesldad, March 4, 1993, Merlda, ?ucaLan, Mexlco.
- Ma[eed M, 8admaev v, ConLe AA, arker !L (2002) ulLerpene lorskolln (Coleus forskohlll, 8enLh). A posslble
new compound for reducuon of body welghL by lncreaslng lean body mass. nuLraCos. March/Aprll, 6-7.
- Ma[eed M, 8admaev v, khan n, rakash L, kalyanam n (2009) A new class of phyLonuLrlenLs for body
welghL managemenL. nuLraloods, 8 (1) 17.
- Cnakpoya l, Pung Sk, erry 8, Wlder 8 and LrnesL L (2011) 1he use of Carclnla exLracL (PydroxyclLrlc Acld) as
a welghL loss supplemenL. A sysLemauc revlew and meLa-analysls of randomlzed cllnlcal Lrlals, !ournal of
CbeslLy, volume 2011, Arucle lu 309038,9 pages. uol:10.1133/2011/309038.
- 1hom L (1996) PydroxyclLraLe (PCA) ln LreaLmenL of obeslLy. lnL. !. CbeslLy 20 (4): 73.
2012 - 2013 SABINSA CORPORATION 14
BP191 9+.+141,+9 P.^1 ,#+ 511, 1^.;$.+1/ 5K +P1 8##/ .,/ ?"$H '/4*,*9+".6#,\ BP191 %"#/$3+9
."1 ,#+ *,+1,/1/ +# /*.H,#91: +"1.+: 3$"1: 4*6H.+1 #" %"1^1,+ .,K /*91.91\
*